These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 10588988)
1. Chlorofluorocarbon to hydrofluoroalkane formulations: an industry perspective. Atkins P J Allergy Clin Immunol; 1999 Dec; 104(6):S268-70. PubMed ID: 10588988 [TBL] [Abstract][Full Text] [Related]
2. The CFC to HFA transition and its impact on pulmonary drug development. Leach CL Respir Care; 2005 Sep; 50(9):1201-8. PubMed ID: 16122403 [TBL] [Abstract][Full Text] [Related]
3. Hydrofluoroalkane mandate in effect January 1, 2009: Switch from chlorofluorocarbon- to hydrofluoroalkane-propelled inhalers requires active transition. Peters S Clin Cornerstone; 2009; 9(3):50-3. PubMed ID: 19781516 [TBL] [Abstract][Full Text] [Related]
4. The chlorofluorocarbon to hydrofluoroalkane transition: the effect on pressurized metered dose inhaler suspension stability. Brindley A J Allergy Clin Immunol; 1999 Dec; 104(6):S221-6. PubMed ID: 10588978 [TBL] [Abstract][Full Text] [Related]
5. [Changes in metered dose inhaler propellants]. Chinet T Rev Mal Respir; 2000 Feb; 17(1):15-20. PubMed ID: 10756552 [TBL] [Abstract][Full Text] [Related]
6. Budesonide administered using chlorofluorocarbon and hydrofluoroalkane pressurized metered-dose inhalers: pharmacokinetics, pharmacodynamics and clinical equivalence. Singh D; Tutuncu A; Lohr I; Carlholm M; Polanowski T Int J Clin Pharmacol Ther; 2007 Sep; 45(9):485-95. PubMed ID: 17907591 [TBL] [Abstract][Full Text] [Related]
7. Transition to CFC-free metered dose inhalers--into the new millennium. McDonald KJ; Martin GP Int J Pharm; 2000 May; 201(1):89-107. PubMed ID: 10867268 [TBL] [Abstract][Full Text] [Related]
9. Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications. Boccuzzi SJ; Wogen J; Roehm JB Clin Ther; 2000 Feb; 22(2):237-47. PubMed ID: 10743983 [TBL] [Abstract][Full Text] [Related]
10. The role of international environmental agreements in metered-dose inhaler technology changes. Forte R; Dibble C J Allergy Clin Immunol; 1999 Dec; 104(6):S217-20. PubMed ID: 10588977 [TBL] [Abstract][Full Text] [Related]
12. Moving from CFC aerosol to HFA aerosol or dry powder inhalers: what do patients think? Hartung TK; Allbutt H; Dewar M; Innes JA; Crompton GK Respiration; 2002; 69(4):314-9. PubMed ID: 12169743 [TBL] [Abstract][Full Text] [Related]
13. Moisture transport into chlorofluorocarbon-free metered dose inhalers. Williams G J Allergy Clin Immunol; 1999 Dec; 104(6):S227-9. PubMed ID: 10588979 [TBL] [Abstract][Full Text] [Related]
14. Developing an in vitro understanding of patient experience with hydrofluoroalkane-metered dose inhalers. Doub WH; Shah V; Limb S; Guo C; Liu X; Ngo D J Pharm Sci; 2014 Nov; 103(11):3648-3656. PubMed ID: 25228114 [TBL] [Abstract][Full Text] [Related]
15. Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug delivery system. Ross DL; Gabrio BJ J Aerosol Med; 1999; 12(3):151-60. PubMed ID: 10623331 [TBL] [Abstract][Full Text] [Related]
16. Development and performance of a new hydrofluoroalkane (HFA 134a)-based metered dose inhaler (MDI) of salmeterol. Peyron ID; Britto IL; Benissan LB; Tardieu BZ Respir Med; 2005 Apr; 99 Suppl A():S20-30. PubMed ID: 15777605 [TBL] [Abstract][Full Text] [Related]
17. Salmeterol HFA is as effective as salmeterol CFC in children and adults with persistent asthma. Chopra N; Williams M; Rimmer M; Kahl L; Jenkins M; Respir Med; 2005 Apr; 99 Suppl A():S1-S10. PubMed ID: 15777603 [TBL] [Abstract][Full Text] [Related]